Arcturus appoints John Markels to Board of Directors
Arcturus Therapeutics Holdings, a late-stage clinical messenger RNA company, has appointed John Markels, Ph.D.
Dr. Markels will provide strategic oversight to the company’s vaccine franchise and manufacturing processes.
He has over 35 years of leadership experience in the pharmaceutical industry at Merck, with a deep background in manufacturing, development, and technology transfer as well as global commercial, policy, and organizational development.
Dr. Markels serves on the Board of Sangamo Therapeutics and chairs and serves on the advisory boards for the University of California, Berkeley College of Chemistry and University of Delaware Department of Chemical and Biomolecular Engineering, respectively.
Dr. Markels retired from Merck in March 2022, most recently as President of Global Vaccines, a large and growing business where he led an integrated team dedicated to discovery and development, supply and access, and global marketing and long-term strategy for the vaccines portfolio.
Earlier roles at Merck included President, Latin America, as well as a long career in senior leadership positions in major regions worldwide in manufacturing technology, operations, supply chain and strategy. Dr. Markels has worked in every region of the world and lived in the U.S., Latin America and Europe. He received his Ph.D. in Chemical Engineering from the University of California, Berkeley and his B.S. in Chemical Engineering from the University of Delaware.
